Published in Cancer Treat Rep on January 01, 1979
Reduction of daunomycin toxicity by razoxane. Br J Cancer (1981) 0.87
Site-dependent response to chemotherapy for carcinoma of the breast. J R Soc Med (1985) 0.78
Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol (1999) 7.59
Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med (1966) 7.30
Mezlocillin: in vitro studies of a new broad-spectrum penicillin. Antimicrob Agents Chemother (1977) 7.24
Infections caused by Pseudomonas aeruginosa. Rev Infect Dis (1983) 7.19
Thienamycin: new beta-lactam antibiotic with potent broad-spectrum activity. Antimicrob Agents Chemother (1979) 5.81
In vitro studies of semisynthetic alpha-(substituted-ureido) penicillins. Appl Microbiol (1971) 5.23
Proceedings: Causes of death in cancer patients. Cancer (1974) 4.56
Infections in cancer patients. Results with gentamicin sulfate therapy. Cancer (1972) 4.47
Fluconazole susceptibility testing of Candida albicans: microtiter method that is independent of inoculum size, temperature, and time of reading. Antimicrob Agents Chemother (1991) 4.36
Fungal infections complicating acute leukemia. J Chronic Dis (1966) 4.07
Azlocillin: in vitro studies of a new semisynthetic penicillin. Antimicrob Agents Chemother (1977) 4.00
Prevention of central venous catheter-related infections by using maximal sterile barrier precautions during insertion. Infect Control Hosp Epidemiol (1994) 3.94
Resistance to ticarcillin-potassium clavulanate among clinical isolates of the family Enterobacteriaceae: role of PSE-1 beta-lactamase and high levels of TEM-1 and SHV-1 and problems with false susceptibility in disk diffusion tests. Antimicrob Agents Chemother (1988) 3.92
Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol (1999) 3.62
In vitro activity of carbenicillin against gram-negative bacilli. J Bacteriol (1968) 3.41
Colitis associated with docetaxel-based chemotherapy in patients with metastatic breast cancer. Lancet (2000) 3.25
Piperacillin: in vitro evaluation. Antimicrob Agents Chemother (1978) 3.21
Emerging fungal pathogens. Eur J Clin Microbiol Infect Dis (1989) 3.14
Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification. J Clin Oncol (2001) 3.06
Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer. J Clin Oncol (2004) 2.95
Zygomycosis in the 1990s in a tertiary-care cancer center. Clin Infect Dis (2000) 2.78
International Conference for the Development of a Consensus on the Management and Prevention of Severe Candidal Infections. Clin Infect Dis (1997) 2.78
Prognostic impact of discordance between triple-receptor measurements in primary and recurrent breast cancer. Ann Oncol (2009) 2.71
Cyclophosphamide (NSC-26271), vincristine (NSC-67574), cytosine arabinoside (NSC-63878), and prednisone (NSC-10023) (COAP) combination chemotherapy for acute leukemia in adults. Cancer Chemother Rep (1972) 2.71
In vitro evaluation of Ro 13-9904. Antimicrob Agents Chemother (1980) 2.67
Multivariate analysis of prognostic factors in metastatic breast cancer. J Clin Oncol (1983) 2.64
Invasive aspergillosis in 2002: an update. Eur J Clin Microbiol Infect Dis (2002) 2.63
Extraskeletal osteosarcoma. A clinicopathologic review of 26 cases. Cancer (1990) 2.56
The nature and control of infections in patients with acute leukemia. Cancer Res (1965) 2.55
Ultrastructural analysis of indwelling vascular catheters: a quantitative relationship between luminal colonization and duration of placement. J Infect Dis (1993) 2.51
Candidiasis in cancer patients. Am J Med (1984) 2.48
Nosocomial infections due to Xanthomonas maltophilia (Pseudomonas maltophilia) in patients with cancer. Rev Infect Dis (1991) 2.47
Clinical pharmacology of ticarcillin (alpha-carboxyl-3-thienylmethyl penicillin, BRL-2288). Antimicrob Agents Chemother (1973) 2.47
PC-904, a new semisynthetic penicillin. Antimicrob Agents Chemother (1978) 2.46
Carbenicillin therapy for pseudomonas infections. JAMA (1971) 2.40
From the Infectious Diseases Society of America. Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. J Infect Dis (1990) 2.39
Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer. J Natl Cancer Inst (1991) 2.38
Impact of selection process on response rate and long-term survival of potential high-dose chemotherapy candidates treated with standard-dose doxorubicin-containing chemotherapy in patients with metastatic breast cancer. J Clin Oncol (1997) 2.36
In vitro studies of alpha-carboxyl-3-thienylmethyl penicillin, a new semisynthetic penicillin. Appl Microbiol (1971) 2.35
Critical analysis of the current American Joint Committee on Cancer staging system for cutaneous melanoma and proposal of a new staging system. J Clin Oncol (1997) 2.32
Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. Protocol 18 Aredia Breast Cancer Study Group. J Clin Oncol (1999) 2.29
Carcinoma of the male breast. Ann Intern Med (1992) 2.27
Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer. J Clin Oncol (1996) 2.27
Carbenicillin therapy of gram-negative bacilli infections. Am J Med Sci (1969) 2.25
Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel. Ann Oncol (2007) 2.24
Comparative in vitro study of SQ26,776. Antimicrob Agents Chemother (1982) 2.23
Stimulation of megakaryocyte and platelet production by a single dose of recombinant human thrombopoietin in patients with cancer. Ann Intern Med (1997) 2.22
In vitro evaluation of cefoperazone. Antimicrob Agents Chemother (1980) 2.22
Survival among women with triple receptor-negative breast cancer and brain metastases. Ann Oncol (2009) 2.21
Locoregional recurrence patterns after mastectomy and doxorubicin-based chemotherapy: implications for postoperative irradiation. J Clin Oncol (2000) 2.19
Pseudomonas bacteremia. Retrospective analysis of 410 episodes. Arch Intern Med (1985) 2.17
Emerging fungal pathogens in immunocompromised patients: classification, diagnosis, and management. Clin Infect Dis (1993) 2.17
Ciprofloxacin-induced nephrotoxicity in patients with cancer. Arch Intern Med (1993) 2.16
New spectrum of fungal infections in patients with cancer. Rev Infect Dis (1989) 2.16
Trichosporon beigelii infection: a review. Rev Infect Dis (1987) 2.15
1997 guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. Infectious Diseases Society of America. Clin Infect Dis (1997) 2.14
Pirbenicillin, a new semisynthetic penicillin with broad-spectrum activity. Antimicrob Agents Chemother (1976) 2.12
Defining prognosis for women with breast cancer and CNS metastases by HER2 status. Ann Oncol (2008) 2.12
Amoxicillin: in vitro and pharmacological studies. Antimicrob Agents Chemother (1972) 2.12
Infections in cancer patients. Cancer Treat Rev (1975) 2.12
Community respiratory virus infections among hospitalized adult bone marrow transplant recipients. Clin Infect Dis (1996) 2.12
Adriamycin chemotherapy--efficacy, safety, and pharmacologic basis of an intermittent single high-dosage schedule. Cancer (1974) 2.10
Low infection rate and long durability of nontunneled silastic catheters. A safe and cost-effective alternative for long-term venous access. Arch Intern Med (1993) 2.10
Multimodal treatment for inflammatory breast cancer. Int J Radiat Oncol Biol Phys (1989) 2.09
Use of tamoxifen for breast cancer: twenty-eight years later. J Clin Oncol (1995) 2.08
Bacteremia caused by Campylobacter-like organisms in two male homosexuals. Ann Intern Med (1984) 2.07
Systemic candidiasis in cancer patients. Am J Med (1984) 2.05
Comparative in vitro study in new cephalosporins. Antimicrob Agents Chemother (1981) 2.04
Ticarcillin therapy of infections. Antimicrob Agents Chemother (1973) 2.01
Comparative in vitro study of teichomycin A2. Antimicrob Agents Chemother (1983) 2.00
Candida krusei fungemia. An escalating serious infection in immunocompromised patients. Arch Intern Med (2000) 1.95
Inflammatory breast cancer: a review. J Clin Oncol (1992) 1.93
Comparative in vitro activities of teichomycin and other antibiotics against JK diphtheroids. Antimicrob Agents Chemother (1983) 1.93
Leukocyte interferon-induced tumor regression in human metastatic breast cancer, multiple myeloma, and malignant lymphoma. Ann Intern Med (1980) 1.91
Biphasic metaplastic sarcomatoid carcinoma of the breast. Ann Oncol (2006) 1.91
Alveolar soft part sarcoma: clinical course and patterns of metastasis in 70 patients treated at a single institution. Cancer (2001) 1.89
Klebsiella bacteremia in cancer patients. Am J Med Sci (1973) 1.87
In vitro studies of BB-K8, a new aminoglycoside antibiotic. Antimicrob Agents Chemother (1973) 1.86
A randomized study of carbenicillin plus cefamandole or tobramycin in the treatment of febrile episodes in cancer patients. Am J Med (1979) 1.86
Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion. Ann Intern Med (1982) 1.85
Phase II trial of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer. J Clin Oncol (1995) 1.85
The relationship between the thrombotic and infectious complications of central venous catheters. JAMA (1994) 1.85
Outcomes of bacteremia in patients with cancer and neutropenia: observations from two decades of epidemiological and clinical trials. Clin Infect Dis (1997) 1.84
Treatment of hepatosplenic candidiasis with liposomal-amphotericin B. J Clin Oncol (1987) 1.83
The natural history of breast cancer patients with brain metastases. Cancer (1979) 1.82